News

2 August 2021, Cambridge, UK  – Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”).

Cambridge, UK, 3 August 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced the closing of its oversubscribed Seed extension, bringing the total Seed round to $45 million. This extension of $34 million was led by Amsterdam-based investment firm Forbion together with global healthcare investors GV (formerly Google Ventures) and Northpond Ventures and supported by founding investors SV Health Investors, and Johnson & Johnson Innovation – JJDC, Inc..

LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an agreement with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.

CAMBRIDGE, UK and NEW YORK, USA, 27 July 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, today announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.

Today we confirmed the appointment of our latest partner hires as part of our expansion plans to open in Ireland.


The firm welcomes two new partners to open Taylor Wessing Ireland* with the support of UK partners James Goold and Alison Dennis.


Adam Griffiths, who was previously a member of the firm's private equity group and relocated to Ireland in 2017, has returned to Taylor Wessing to lead operations in Dublin.

Click here to view the July edition of Dates for Your Diary


Alderley Park, Cheshire – Infex Therapeutics is pressing ahead with a major development of its pandemic resilience strategy by today announcing an agreement with CRUK Newcastle Drug Discovery Unit. This will in-licence a novel therapy designed to treat SARS-CoV-2 along with future variants and a broad spectrum of coronaviruses.


The program, PAN-X, is an early stage drug that has shown encouraging activity during in-vitro testing.

Read the full People Pathways newsletter here.


  • Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor

  • Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology

Pages